In its first full fiscal year outlook since completing the $62bn acquisition of Shire PLC in early January, Takeda Pharmaceutical Co. Ltd. expects the newly merged business to achieve "flat to slightly declining" underlying revenue growth, affected in part by increased US generic competition to one of its top products.
A mid-twenties percentage increase in underlying core earnings margin is foreseen, while underlying core EPS should be in the JPY350-370...








